Science
Mechanism of Action
Operating as a potent cell-communicating and skin-identical ingredient, SH-OLIGOPEPTIDE-1 (EGF) actively stimulates the endogenous production of vital skin components, including collagen, elastin, and hyaluronic acid. When applied topically, it binds to specific receptors on keratinocytes, activating intracellular pathways that accelerate the generation of new skin cells and the synthesis of structural proteins. This mechanism facilitates rapid skin repair, enhances the rate of self-regeneration, improves blood vessel formation, and strengthens the skin barrier function through the proliferation of keratinocytes, endothelial cells, and fibroblasts. The outcome is improved skin texture, reduced fine lines, and long-term moisturization.
Research
Clinical Evidence
High confidenceN/A
Key findings
- 01 Studies indicate that oligopeptide-1 significantly elevates elastin and type I collagen precursor content in the skin, yielding visible wrinkle reduction effects.
- 02 Formulations containing sh-Oligopeptide-1 have been shown to strongly promote skin cell division and growth, stimulate the synthesis and secretion of extracellular macromolecules like hyaluronic acid and glycoproteins, and reduce the appearance of wrinkles and fine lines.
- 03 A 2012 study involving barley bioengineered epidermal growth factor (sh-Oligopeptide-1) demonstrated statistically significant improvements in fine lines, rhytids, skin texture, pore size, and various dyschromatic conditions within the first month, with continued enhancement over three months.
- 04 An EGF-containing cream (sh-Oligopeptide-1) notably increased skin moisture and elasticity and decreased transepidermal water loss (TEWL) after one week, signifying an improved skin barrier function.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
This specific form of sh-Oligopeptide-1 (SpecBio™EGF Plus) is designed for stable biological activity at room temperature, overcoming the common requirement for low-temperature storage. For optimal integration into formulations, it should be incorporated as the final step, ensuring the temperature remains below 45℃.
Safety
Safety Profile
For SH-OLIGOPEPTIDE-1 (human Epidermal Growth Factor), the Cosmetic Ingredient Review (CIR) lists statuses ranging from 'Safe Ingredients With Qualifications' to 'Ingredients for Which the Data are Insufficient.' As a growth factor, there is a theoretical potential for tumorigenesis with overexpression or dysregulation, given EGF signaling is involved in many tumor cells; thus, growth factor-mimetic applications warrant caution. While sh-EGF is authorized as a cosmetic in certain concentrations, 'unknown long-term risks' have been noted. Active EGF is considered an unauthorized potent drug, and topical human recombinant EGF (hr-EGF) is not authorized as a medication outside of clinical trials. Importantly, no specific SCCS or FDA regulatory status for the complete ingredient, SH-OLIGOPEPTIDE-1 SR-OCEAN POUT OLIGOPEPTIDE-1 DIPEPTIDE-39, was found in the provided research.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While the core component sh-Oligopeptide-1 demonstrates significant anti-aging and regenerative benefits in studies, the comprehensive safety profile and long-term risks of the full ingredient blend remain largely undetermined, warranting cautious application.
Related
Similar Ingredients
Finding similar ingredients…